Christophe dombu
Stock Analyst at Kepler Capital
(0.15)
# 4,678
Out of 5,055 analysts
98
Total ratings
41.2%
Success rate
-10.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $27.88 | - | 1 | Jun 4, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Sell | €23.50 | €26.04 | -9.75% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Reiterated: Buy | 1,462p | 1,050p | +39.24% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Reiterated: Buy | €415.00 | €335.00 | +23.88% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Reiterated: Buy | CHF 38.00 | CHF 18.79 | +102.24% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Reiterated: Buy | CHF 69.00 → CHF 70.00 | CHF 66.50 | +5.26% | 27 | Apr 13, 2026 | |
| EPA: MAAT MaaT Pharma SA | Reiterated: Buy | €17.00 | €0.94 | +1,706.59% | 26 | Mar 31, 2026 | |
| EPA: ALVIO Valerio Therapeutics Société anonyme | Downgraded: Sell | €0.10 → €0.01 | €0.41 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $27.88
Upside: -
Lakefront Biotherapeutics NV
May 7, 2026
Reiterated: Sell
Price Target: €23.50
Current: €26.04
Upside: -9.75%
Smith & Nephew plc
May 6, 2026
Reiterated: Buy
Price Target: 1,462p
Current: 1,050p
Upside: +39.24%
Virbac SA
Apr 17, 2026
Reiterated: Buy
Price Target: €415.00
Current: €335.00
Upside: +23.88%
Kuros Biosciences AG
Apr 14, 2026
Reiterated: Buy
Price Target: CHF 38.00
Current: CHF 18.79
Upside: +102.24%
Basilea Pharmaceutica AG
Apr 13, 2026
Reiterated: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: CHF 66.50
Upside: +5.26%
MaaT Pharma SA
Mar 31, 2026
Reiterated: Buy
Price Target: €17.00
Current: €0.94
Upside: +1,706.59%
Valerio Therapeutics Société anonyme
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: €0.41
Upside: n/a